COVID-19 vaccine: SPIKEVAX (elasomeran)
Published
Last updated
Related content
- Moderna’s COVID-19 vaccine SPIKEVAX receives approval for full registrationThe TGA has approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration.
- TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and olderOn 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, SPIKEVAX (elasomeran), for use as a booster dose in individuals aged 12 years and older.
- TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age groupThe TGA has granted provisional approval to Moderna Australia Pty Ltd in relation to the COVID-19 vaccine, Spikevax (elasomeran), for individuals aged 12 years and over.